Main > ONCOLOGY (**) > Lymphoma>NHL>B-Cell>DLBCL*** > 1st Line TREAT.: > USA. G. CD79B Marker Inhibitor+

---

USA. G. CD79B Marker Inhibitor+'s subsections
(*) USA Approval Date: 2023. 04.19
+R-CHP
Company
Generic Name
TM
TM Web-Site
USA Patent Numbers

USA. G. CD79B Marker Inhibitor+'s products
This section has no products